Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT05631574
What this trial is testing

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Who this might be right for
Non Small Cell Lung CancerPancreatic CancerColorectal Cancer+14 more
Biomea Fusion Inc. 13
Testing effectiveness (Phase 2)Study completedNCT03543813
What this trial is testing

PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

Who this might be right for
Solid Tumor, AdultHead and Neck CancerNon Small Cell Lung Cancer+2 more
CytomX Therapeutics 133
Not applicableUnknownNCT05486988
What this trial is testing

CtDNA as a Biomarker for Treatment in Advanced NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Fuzhou General Hospital 500
Testing effectiveness (Phase 2)Active Not RecruitingNCT07005336
What this trial is testing

Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
TJ Biopharma Co., Ltd. 150
Testing effectiveness (Phase 2)Active Not RecruitingNCT04579380
What this trial is testing

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Who this might be right for
Uterine NeoplasmsUterine Cervical NeoplasmsBiliary Tract Neoplasms+3 more
Seagen, a wholly owned subsidiary of Pfizer 217
Early research (Phase 1)Study completedNCT01199068
What this trial is testing

CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Daiichi Sankyo Co., Ltd. 15
Large-scale testing (Phase 3)Active Not RecruitingNCT05048797
What this trial is testing

Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca 454
Large-scale testing (Phase 3)Active Not RecruitingNCT06151574
What this trial is testing

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Who this might be right for
Lung Cancer, Non-squamous, Non-small Cell
Boehringer Ingelheim 428
Testing effectiveness (Phase 2)Looking for participantsNCT07730021
What this trial is testing

ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumors
Astellas Pharma Global Development, Inc. 392
Testing effectiveness (Phase 2)Active Not RecruitingNCT05635708
What this trial is testing

Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung CancerMetastatic Non-small Cell Lung Cancer
BeiGene 400
Early research (Phase 1)Active Not RecruitingNCT05907304
What this trial is testing

Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

Who this might be right for
Advanced or Metastatic Solid Tumors
Erasca, Inc. 86
Testing effectiveness (Phase 2)Active Not RecruitingNCT05620134
What this trial is testing

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Who this might be right for
CancerTumor, SolidAdvanced Solid Tumor+19 more
Salubris Biotherapeutics Inc 263
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine 156
Early research (Phase 1)Looking for participantsNCT07094204
What this trial is testing

Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Who this might be right for
Solid TumorNon-Small-Cell Lung CancerPancreatic Ductal Adenocarcinoma+1 more
Astellas Pharma Inc 364
Testing effectiveness (Phase 2)Study completedNCT00074022
What this trial is testing

GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors

Who this might be right for
Recurrent Non-small Cell Lung CancerRecurrent Prostate CancerStage III Prostate Cancer+5 more
National Cancer Institute (NCI) 48
Testing effectiveness (Phase 2)Looking for participantsNCT05269381
What this trial is testing

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8+98 more
Mayo Clinic 138
Testing effectiveness (Phase 2)Looking for participantsNCT07264816
What this trial is testing

BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC

Who this might be right for
Non-squamous Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 80
Testing effectiveness (Phase 2)Looking for participantsNCT05267626
What this trial is testing

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Who this might be right for
Advanced Solid TumorMetastatic CancerCutaneous Melanoma+1 more
Aulos Bioscience, Inc. 159
Early research (Phase 1)Study completedNCT02443324
What this trial is testing

Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Who this might be right for
Gastric AdenocarcinomaAdenocarcinoma of the Gastroesophageal JunctionNon-small Cell Lung Cancer+2 more
Eli Lilly and Company 175
Large-scale testing (Phase 3)Looking for participantsNCT07005102
What this trial is testing

Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
AbbVie 854
Next Page